Tirzepatide
Dual GIP and GLP-1 Receptor Agonist
Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Available as FDA-approved Mounjaro® for Type 2 diabetes and Zepbound® for weight management and obstructive sleep apnea. It provides superior weight loss and glycemic control compared to single-pathway medications through its unique dual mechanism of action.
Comprehensive Dosing Guide
Quick Reference
Frequency
Once Weekly
Same day each week
Timing
Any Time of Day
With or without food
Dose Increase
+2.5mg
Every 4 weeks as needed
Weight Loss Dosing Schedule
Follow this escalation schedule for optimal weight loss results. Each dose is maintained for 4 weeks before increasing to allow your body to adjust.
Starting dose — helps your body adjust to the medication
First increase — therapeutic effects begin
Continue if tolerating well
Increased efficacy for weight loss
Near-maximum dose
Maximum maintenance dose for weight management
Type 2 Diabetes Dosing Schedule
For blood sugar control, dosing is similar but maintenance doses are often lower. Your doctor will adjust based on your A1C levels and tolerance.
Starting dose — does not control blood sugar yet
First therapeutic dose for glucose control
Standard maintenance dose for most patients
Maximum dose if additional control needed
Expected Results Timeline
Week 4-8
Initial Response
Appetite reduction and early weight changes become noticeable. Most experience 2-4% body weight loss.
Week 12-16
Significant Progress
5-10% body weight loss typical. Blood sugar improvements stabilize for diabetics.
Week 72
Peak Results
Maximum weight loss achieved (15-22% average in trials). Optimal metabolic benefits.
How to Inject
Injection Sites
Rotate between abdomen, thigh, or upper arm each week to prevent skin issues
Same Day Weekly
Pick a consistent day that works for your schedule — you can change if needed
Flexible Timing
Any time of day works, with or without food — just stay consistent
Never Double Dose
If you miss a dose, take it as soon as you remember within 4 days. Otherwise, skip it.
Important: Long-Term Use Required
Weight regain is common after discontinuation. Clinical studies show most patients regain weight within 12 months of stopping treatment. Tirzepatide is designed for long-term use as part of a comprehensive weight management plan.
Medical Disclaimer
Tirzepatide is FDA-approved as Mounjaro® for Type 2 diabetes and Zepbound® for chronic weight management. This information is for educational purposes and should not replace consultation with healthcare providers. Individual results may vary. Prescribing information and medical supervision are required for all therapeutic uses.